Highlights Nuvectis Pharma, Inc.

Equities

NVCT

US67080T1088

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
6.2 ^USD	-4.76%		-4.62%	-25.66%

Jul. 01	Nuvectis Pharma, Inc.(NasdaqCM:NVCT) dropped from Russell Small Cap Comp Growth Index	CI
Jul. 01	Nuvectis Pharma, Inc.(NasdaqCM:NVCT) dropped from Russell 2000 Dynamic Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	Apr. 08	CI
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	Mar. 14	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial	23-09-12	CI
Nuvectis Pharma's NXP800 Cholangiocarcinoma Treatment Candidate Gets US FDA Orphan Drug Label	23-08-17	MT
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Nuvectis Pharma Says US FDA Cleared Investigational New Drug Application for Oncology Drug Candidate NXP900	23-05-15	MT
Nuvectis Pharma Inc. Announces FDA Clearance of NXP900 IND	23-05-15	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Nuvectis Pharma, Inc. Announces Initiation of the Phase 1B Study for NXP800 in Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma	23-04-10	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI
Nuvectis Pharma, Inc. Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States	23-01-04	CI
Nuvectis Pharma's Ovarian Cancer Therapy Receives US FDA's Fast Track Designation; Shares Rise	22-12-01	MT
Nuvectis Pharma, Inc. Announces Fda Grants Fast Track Designation to Nuvectis Pharma's Nxp800 for the Treatment of Platinum-Resistant, Arid1a-Mutated Ovarian Carcinoma	22-12-01	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Earnings Flash (NVCT) NUVECTIS PHARMA Reports Q3 Loss $-0.42	22-11-08	MT
Nuvectis Pharma Announces Positive Data for NXP800 in A Preclinical Model of ARID1a-Mutated Gastric Carcinoma	22-09-13	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nuvectis Pharma, Inc.

Equities

NVCT

US67080T1088

Highlights

Filters